AU2018243836B9 - Gut-selective sequestering agents for the treatment and prevention of autism and related disorders - Google Patents

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders Download PDF

Info

Publication number
AU2018243836B9
AU2018243836B9 AU2018243836A AU2018243836A AU2018243836B9 AU 2018243836 B9 AU2018243836 B9 AU 2018243836B9 AU 2018243836 A AU2018243836 A AU 2018243836A AU 2018243836 A AU2018243836 A AU 2018243836A AU 2018243836 B9 AU2018243836 B9 AU 2018243836B9
Authority
AU
Australia
Prior art keywords
sequestrant
subject
activated carbon
mice
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018243836A
Other languages
English (en)
Other versions
AU2018243836B2 (en
AU2018243836A1 (en
Inventor
Anthony Stewart Campbell
David H. Donabedian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axial Therapeutics Inc
Original Assignee
Axial Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axial Therapeutics Inc filed Critical Axial Therapeutics Inc
Publication of AU2018243836A1 publication Critical patent/AU2018243836A1/en
Assigned to AXIAL THERAPEUTICS, INC. reassignment AXIAL THERAPEUTICS, INC. Amend patent request/document other than specification (104) Assignors: AXIAL BIOTHERAPEUTICS, INC.
Publication of AU2018243836B2 publication Critical patent/AU2018243836B2/en
Application granted granted Critical
Publication of AU2018243836B9 publication Critical patent/AU2018243836B9/en
Priority to AU2021206871A priority Critical patent/AU2021206871B2/en
Priority to AU2022200220A priority patent/AU2022200220A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2018243836A 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders Ceased AU2018243836B9 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021206871A AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480039P 2017-03-31 2017-03-31
US62/480,039 2017-03-31
PCT/US2018/025607 WO2018183986A1 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021206871A Division AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Publications (3)

Publication Number Publication Date
AU2018243836A1 AU2018243836A1 (en) 2019-11-21
AU2018243836B2 AU2018243836B2 (en) 2021-04-22
AU2018243836B9 true AU2018243836B9 (en) 2021-05-13

Family

ID=63677186

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2018243836A Ceased AU2018243836B9 (en) 2017-03-31 2018-03-31 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2021206871A Ceased AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A Abandoned AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021206871A Ceased AU2021206871B2 (en) 2017-03-31 2021-07-22 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
AU2022200220A Abandoned AU2022200220A1 (en) 2017-03-31 2022-01-14 Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Country Status (9)

Country Link
US (4) US10617718B2 (enExample)
EP (1) EP3600349A4 (enExample)
JP (1) JP6978122B2 (enExample)
KR (1) KR102328323B1 (enExample)
CN (2) CN110944650B (enExample)
AU (3) AU2018243836B9 (enExample)
BR (1) BR112019020289A2 (enExample)
CA (2) CA3191747A1 (enExample)
WO (1) WO2018183986A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2021011481A1 (en) * 2019-07-12 2021-01-21 The General Hospital Corporation Anti-inflammatory factors
JP7607659B2 (ja) * 2019-12-19 2024-12-27 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド トマトの搾りかすを用いたイヌの上昇した４－エチルフェニル硫酸と関連付けられた状態の治療およびリスクを低減する組成物および方法ならびにそのような状態のリスクにあるイヌを特定する方法
US20240197795A1 (en) * 2020-07-27 2024-06-20 Boadie DUNLOP Assessment and treatment of depression, anxiety, or related disorders
CN113440522B (zh) * 2021-07-29 2022-12-13 中山大学附属第七医院(深圳) 一种吲哚丙酸在制备用于治疗自闭症药物中的应用
CN115825314A (zh) * 2021-09-17 2023-03-21 中国科学院深圳先进技术研究院 一种阿尔兹海默症生物标志物s-甲基-5′-硫代腺苷及其应用
WO2023154966A1 (en) * 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Compositions and methods for sequestering metabolites in the gastrointestinal tract
WO2023154547A1 (en) 2022-02-14 2023-08-17 Axial Therapeutics, Inc. Colon targeted drug delivery
CN116990395A (zh) * 2022-04-26 2023-11-03 中国科学院深圳先进技术研究院 一种基于粪便的阿尔兹海默症生物标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065132A1 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761284A (en) * 1977-12-27 1988-08-02 Kureha Kagaku Kogy Kabushiki Kaisha Antidote including activated carbon particles
JPS5673542A (en) * 1979-11-22 1981-06-18 Kureha Chem Ind Co Ltd Adsorbent
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US7651974B2 (en) 2002-11-01 2010-01-26 Kureha Chemical Industry Co., Ltd. Adsorbent for oral administration
JP2008523100A (ja) * 2004-12-13 2008-07-03 アリーナ ファーマシューティカルズ， インコーポレイテッド ５ｈｔ２ｃ受容体に関連した疾患の治療に有用な５ｈｔ２ｃ受容体のモジュレータとしてのｎ−ビアリール及びｎ−アリールヘテロアリール２−置換ピペラジン誘導体
WO2010102218A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
KR101593287B1 (ko) * 2011-03-04 2016-02-11 가부시끼가이샤 구레하 정제형의 경구 투여용 조성물 및 그의 제조 방법
US20140213534A1 (en) * 2011-05-23 2014-07-31 Thomas Jefferson University Intestinal hyperpermeability and prevention of systemic disease
GB201204696D0 (en) * 2012-03-16 2012-05-02 Ucl Business Plc Therapy
TWI520751B (zh) 2013-02-22 2016-02-11 吳羽股份有限公司 經口投予用吸附劑及腎疾病治療劑及肝疾病治療劑
MX2016000293A (es) 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
KR20160034352A (ko) * 2013-07-23 2016-03-29 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
US9763903B2 (en) * 2013-10-22 2017-09-19 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
US20150111878A1 (en) * 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2015150590A1 (en) * 2014-04-04 2015-10-08 Biotechnobel Sa Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract
KR102328323B1 (ko) 2017-03-31 2021-11-19 엑시얼 테라퓨틱스, 인크. 자폐증 및 관련 장애의 치료 및 예방을 위한 장-선택적 봉쇄제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140065132A1 (en) * 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder

Also Published As

Publication number Publication date
CN114569633A (zh) 2022-06-03
US11007219B2 (en) 2021-05-18
NZ758692A (en) 2022-03-25
BR112019020289A2 (pt) 2020-09-01
AU2018243836B2 (en) 2021-04-22
EP3600349A4 (en) 2020-09-30
CA3095724A1 (en) 2018-10-04
AU2021206871B2 (en) 2021-10-14
CA3191747A1 (en) 2018-10-04
AU2022200220A1 (en) 2022-02-10
US20230364135A1 (en) 2023-11-16
US20180303876A1 (en) 2018-10-25
CN110944650B (zh) 2022-03-04
JP6978122B2 (ja) 2021-12-08
KR102328323B1 (ko) 2021-11-19
JP2020513032A (ja) 2020-04-30
KR20200024133A (ko) 2020-03-06
AU2021206871A1 (en) 2021-08-12
CA3095724C (en) 2023-04-18
WO2018183986A1 (en) 2018-10-04
CN110944650A (zh) 2020-03-31
AU2018243836A1 (en) 2019-11-21
US10617718B2 (en) 2020-04-14
CN114569633B (zh) 2023-11-17
EP3600349A1 (en) 2020-02-05
US20200368276A1 (en) 2020-11-26
US20200390809A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
AU2021206871B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
JP2022088641A (ja) 細菌株を含む組成物
ES2859758T3 (es) Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intestinal
AU2013234099B2 (en) Porous carbon particles for use in the treatment or prevention of liver disease
Zhai et al. Probiotics bring new hope for atherosclerosis prevention and treatment
JP2022517754A (ja) 菌株、組成物および使用方法
Nápoles-Medina et al. Oral administration of Lactobacillus inhibits the permeability of blood‐brain and gut barriers in a parkinsonism model
KR20220094211A (ko) 세로토닌 생산 박테리아
KR20220034816A (ko) 박테리아 균주를 포함하는 조성물
JP2023512653A (ja) 細菌株を含む組成物
Qi et al. Lactiplantibacillus plantarum SG5 inhibits neuroinflammation in MPTP-induced PD mice through GLP-1/PGC-1α pathway
Shi et al. Production, mechanisms, and therapeutic strategies of tryptophan metabolites in CNS diseases
Wang et al. Alternate-day fasting ameliorates α-synuclein pathology and suppresses inflammation via the gut-brain axis in an MPTP-induced subacute mouse model of Parkinson’s disease
WO2016053142A1 (ru) Композиция для детоксикации организма
NZ785988A (en) Gut-selective sequestering agents for the treatment and prevention of autism and
JP2001158743A (ja) 乳酸菌含有組成物、医薬及び食品
NZ758692B2 (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
HK40075263A (en) Gut-selective sequestering agents for the treatment and prevention of autism and related disorders
WO2023154966A1 (en) Compositions and methods for sequestering metabolites in the gastrointestinal tract
NZ760605B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: AXIAL THERAPEUTICS, INC.

Free format text: FORMER NAME(S): AXIAL BIOTHERAPEUTICS, INC.

SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired